Different types of inner ear diseases can damage different cochlear subsites by different mechanisms. Steroids administered by different methods are commonly used for treating inner ear diseases. There is reason to believe that dexamethasone (Dex) may reach cochlear subsite targets via different pathways after administration by different methods: Intratympanic (IT), postaural (PA), and intraperitoneal (IP). The purpose of this study was to explore the cochlear concentration and distribution of Dex after administration by different methods. High-performance liquid chromatography-mass spectrometry and immunofluorescence technology were employed to measure and compare the Dex concentration in the perilymph and cochlear tissue and the cochlear distribution of Dex. IT administration resulted in higher Dex concentrations in the perilymph and cochlear tissues than those with the other administration methods. Intratympanic and postaural administration could result in higher Dex concentrations in the organ of Corti than systemic administration, but systemic administration could result in higher Dex concentrations in the stria vascularis than the other administration methods. A decreasing basal-apical gradient of Dex uptake was present in the cochlea after IT but not IP or PA administration. These results indicate that different administration methods result in different Dex distributions, which can be attributed to features of the cochlear vascular system and intracochlear diffusion. Our results provide clinicians with an experimental basis for the use of different steroid injection routes to optimize the effects on inner ear diseases with different target organs.
Introduction
The prevalence of inner ear diseases, such as sudden sensorineural hearing loss (SSNHL), Meniere disease (MD), and noiseinduced hearing loss, is increasing due to an increase in life expectancy, noise exposure and the use of ototoxic medicines (Kim, 2017) . Patients with inner ear diseases complain about hearing loss, vertigo or tinnitus. Different types of inner ear diseases can damage different cochlear subsites by different mechanisms (Creber et al., 2018) . For example, the organ of Corti is the primary site of injury in noise-induced hearing loss and aminoglycoside ototoxicity (Hirose et al., 2005; Sato et al., 2010) ; however, the stria vascularis is primarily damaged in autoimmune hearing loss and MD (Kariya et al., 2009; Lin and Trune, 1997; Ohlemiller et al., 2008; Tagaya et al., 2011) .
Corticosteroid treatment for inner ear diseases such as SSNHL and MD is well accepted, commonly used, and has high efficacy, as suggested by many clinical trials (Garduno-Anaya et al., 2005; Stachler et al., 2012; Wilson et al., 1980) . Steroids affect SSNHL in many ways, such as inhibiting immune responses, influencing the microvascular circulation, exerting mineralocorticoid effects and reducing the endolymphatic pressure (Mort and Bronstein, 2006; Schreiber et al., 2010) . High-dose systemic steroids are the current standard treatment for SSNHL; however, this treatment may result in many adverse effects, such as partial inhibition of the hypothalamicpituitary-adrenal axis, changes in mood, increased blood glucose or blood pressure, gastritis, and sleep disorders (Henzen et al., 2000; Stachler et al., 2012; Weinstein, 2012) . Intratympanic (IT) administration of steroids to treat SSNHL is a promising method that maintains high steroid levels in the perilymphatic fluid while simultaneously avoiding the complications of systemic steroids (El et al., 2017; Rauch, 2008; Rauch et al., 2011) . In 2012, the American Academy of Otolaryngology Head and Neck Surgery recommended IT steroids as an initial treatment rather than salvage therapy in patients with SSNHL (Stachler et al., 2012) . Although IT steroids present less potential toxicity than systemic steroids, they can also cause many infrequent and transient complications, such as pain, persistent tympanic membrane perforation, and dizziness; IT steroids are also costly and require multiple visits (Rauch et al., 2011; Stachler et al., 2012) . Postauricular (PA) steroid administration has been popular for treating SSNHL in China since it was first used for treating intractable low-frequency sensorineural hearing loss (Yang et al., 2007) . PA steroids can not only avoid many side effects resulting from systemic and IT steroids but also present satisfactory therapeutic effects (Li et al., 2013) . The Chinese Society of Otorhinolaryngology Head and Neck Surgery released its latest version of guidelines for sudden deafness in 2015, which recommended the use of PA corticosteroids for patients who do not recover with systemic corticosteroids. Although many clinical studies have been conducted to compare the efficacy of different administration methods, the results remain controversial (Ahn et al., 2008a,b; Ermutlu et al., 2017; Filipo et al., 2010; Stachler et al., 2012) .
In recent years, many studies have been conducted to explore the pharmacokinetic concentration of dexamethasone (Dex) in perilymph using high-performance liquid chromatography (HPLC) and high-performance liquid chromatography-mass spectrometry (LC-MS) (Bird et al., 2011; Liu et al., 2006; Salt et al., 2012; Tobita et al., 2002; Wang et al., 2009; Yang et al., 2008) . HPLC used to measure substances has many disadvantages, such as a long elution time and low sensitivity. LC-MS, which has a short analysis time and high efficiency for identification and separation, has been used to measure steroids and is currently considered the most accurate method for steroid quantification (Handelsman and Wartofsky, 2013; Lv et al., 2018; Wudy et al., 2018) . Because the cochlear aqueduct allows the perilymph to mix with cerebrospinal fluid (CSF), it is possible that not all drugs in the perilymph arrive in cochlear tissue (Salt and Hirose, 2018) . Investigators have recently demonstrated that IT drugs can reach the brain and spinal fluid in experimental animals (Dean et al., 2012; Lee et al., 2012; Zhang et al., 2012) , meaning that the amount of drug in the perilymph does not reflect the actual value in cochlear tissue. In this study, we use LC-MS to simultaneously estimate and compare the cochlear and perilymphatic pharmacokinetics of Dex administered by three different methods (intraperitoneal (IP), IT, and PA).
Based on the current pathology, it is critical to choose the most appropriate method for administering Dex to treat inner ear diseases by understanding the pharmacokinetics and distribution of Dex in cochlear tissue and how they differ by administration method. In this study, (1) we used LC-MS to measure the pharmacokinetics of Dex in the perilymph and cochlear tissue and (2) immunofluorescence to explore the cochlear Dex distribution after injection by three different methods.
Methods

Design
The present study contained two parts. In part 1, we used LC-MS to explore the concentration of Dex in the perilymph and cochlear tissue at different times after administration by three different methods (IP, IT, PA) and determine the times when each regime resulted in the maximal Dex concentration in the cochlea. In part 2, we used immunofluorescence to investigate the cochlear distribution of Dex after IP, IT, and PA administration when each regime resulted in the maximal Dex concentration, according to the results of part 1.
Animal studies
The experiments were approved by the ethics committee of Peking University Peoples' Hospital (Beijing, China). The guidelines for the Care and Use of Laboratory Animals set by the China Association of Laboratory/Animal Care were also applied for these experiments.
Specific-pathogen-free male adult guinea pigs that were 7e8 weeks old and weighed 250e300 g were purchased from the Peking University Laboratory Animal Centre. Guinea pigs who had healthy external auditory canals and tympanic membranes examined with an automicroscope were employed in this study. They were individually raised at an appropriate temperature (20e22 C) and humidity (55e65%) under a 12-h light/dark cycle with free access to standard water and feed. All animals were intraperitoneally anaesthetized with ketamine(60 mg/kg) and xylazine (4 mg/ kg). The animals were divided into four groups according to the administration method employed: the control group (systemic saline administration) (n ¼ 4); IP administration (n ¼ 4); IT administration (n ¼ 4); and PA administration (n ¼ 4). The details of each administration were as follows.
IP: After the animals were anaesthetized, the animals received an intraperitoneal injection of Dex solution at 1 ml/kg.
IT: After the animals were anaesthetized, 10 mg/ml Dex was administered slowly through the anterosuperior quadrant of the right tympanic membrane using a surgical microscope. An approximate 50-ml volume of Dex was injected until the middle ear was entirely full. After the injection, each animal was maintained in a right-ear-up position for 30 min.
PA: After the animals were anaesthetized, Dex at 1 ml/kg was administered slowly through the middle of the right retroauricular groove.
Control group: After the animals were anaesthetized, they received an intraperitoneal injection of saline at 1 ml/kg.
The formulation applied in our study is markedly different from those used in prior studies where dexamethasone-phosphate solution or a dexamethasone suspension was used as a conventional formulation (Salt et al., 2012; Wang et al., 2009) . Dexamethasone has the shortcoming of low solubility. Although the polar molecular properties of dexamethasone phosphate confer higher aqueous solubility, this form is substantially less permeable through the round window membrane (RWM) and vasculature than dexamethasone (Salt and Plontke, 2018) . Dimethyl sulphoxide (DMSO) is regarded as a polar amphipathic solvent and is used to dissolve hydrophobic substances. Moreover, 1% DMSO has been shown to cause no functional or morphological changes in the inner ear (Roldan-Fidalgo et al., 2014) . In this study, Dex (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 1% DMSO at a concentration of 10 mg/ml. The total volume given for IP and PA administration was identical at approximately 1 ml/kg. The actual volume given to the IT group was 50 ml (0.5 mg). The systemic and local doses in this study were selected because they are the standard formulations for patients with SSNHL in our clinic.
Part 1
In this experiment, the pharmacokinetics of Dex injected by three different methods in the perilymph and cochlear tissue were investigated in guinea pigs with a positive Preyer reflex. At 1 h, 2 h, 4 h, 6 h, 12 h, 1 day and 3 days after injection, all animals were intraperitoneally anaesthetized with ketamine (60 mg/kg) and xylazine (4 mg/kg). Perilymph samples were first collected, and the perilymph sampling process was described in detail in previous studies (Liu et al., 2006; Wang et al., 2011) . After the animals were anaesthetized, the skin behind the ear was clipped and sterilized using povidone-iodine. A postauricular incision was made and the muscles were carefully retracted from over the bulla. We used a dental burr to drill a hole through the bulla such that the middle ear was exposed and accessible. The cochlea and RWM were observed clearly using a surgical microscope. After the mucosal tissue of the cochlea was removed, the area was washed with saline to eliminate any potential Dex contamination. Then, the area was dried with tissue wicks. The needle of a microsyringe was directly advanced 1.0 mm through the RWM to the scala tympani. Perilymph was then steadily aspirated at a rate of 1 ml/min. Approximately 10 ml of perilymph was collected and the needle was then slowly withdrawn. Samples contaminated by blood or filled with air were discarded. All samples were immediately stored at À20 C. Then, the animals were sacrificed by cervical dislocation. The inner ear was quickly removed from the skull and middle ear. Subsequently, the ossicles were removed, and small perforations were created in the RWM and at the cochlear apex under a microscope. Phosphate-buffered saline (PBS) was slowly injected through the cochlear apex three times to completely clear the perilymph from the cochlear tissue. Then, the samples were rinsed with PBS and homogenized with 1 ml of lysis solution. The homogenate was centrifuged at 12000 rpm for 20 min, and the supernatant was subsequently used for steroid extraction. Then, the samples of cochlear supernatant were stored at À20 C.
LC-MS
Diluted perilymph and cochlear tissue samples were thawed. The perilymph and cochlear tissue samples were analysed using an LC-MS/MS system equipped with a UHPLC Dionex UltiMate 3000 and Q-Exactive hybrid quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, USA). For chromatographic separation, an Acquity UHPLC BEH C 18 column (2.1 mm Â 50 mm, 1.7 mm) was applied with a column temperature of 40 C. The mobile phase consisted of eluent A (0.1% formic acid in water, v/v) and eluent B (acetonitrile) at a flow rate of 0.2 ml/min. The elution gradient was as follows: 0e0.5 min, 5% A; 0.5e1.0 min, 5e40% A; 1.0e4.0 min, 40e50% A; 4.0e6.0 min, 50e65% A; 6.0e8.0 min, 65e100% A; 8.0e10.0 min, 100% A; 10.0e12.0 min, 5% A. The autosampler was maintained at 10 C with an injection volume of 5 ml for all samples. For MS separation, a Q-Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, USA) equipped with heat electrospray ionization (HESI) was used in full-scan mode. The flow rates of the sheath gas, auxiliary gas and sweep gas were 30, 10 and 0 (arbitrary units), respectively, with a spray voltage of þ3.5 kV and À2.8 kV in the positive and negative modes. The capillary and auxiliary gas heater temperatures were 320 C and 300 C, respectively. The S-lens RF level was maintained at 50 V. Nitrogen was used for stabilizing the spray and as the damping gas in the Ctrap. The automatic gain control (AGC) target (the number of ions to fill the C-trap) was maintained at 3.0 e6, with 200 ms as the maximum injection time. In addition, the full MS scan ranges were set between 100 and 1500 m/z with a resolution of 70,000. In MS/ MS mode, the stepped normalized collision energy (NCE) was set at 20, 50, and 100 eV. The MS/MS information of all the compounds was obtained, and the data were processed using Thermo Xcalibur 3.0 software (Thermo Fisher Scientific, San Jose, USA). The elements in use (C 0e40, H 0e80, O 0e30, Na 0e1) and the mass tolerance (<5 ppm for diterpenes, lactones and flavonoids and <10 ppm for phenolic acids) were set accordingly to narrow down the options for the molecular analysis. Serially diluted solutions of Dex were run to create a reference calibration curve with a reproducible linear relationship with a lower test limit of 10 ng/ml. The perilymph and cochlear tissue samples were analysed for Dex concentrations.
The methodological verification results of LC-MS for measuring Dex in the perilymph and cochlear tissues of guinea pigs are shown below. Dex in cochlear tissue: Dex is linear in the range of 10e5000 ng/ml. The relative error (RE) of different concentrations of quality control samples was between À10.56% and 5.46%. The intra-and interday relative standard deviation (RSD) values ranged from 3.09% to 4.34% and 3.95%e4.57%, respectively. Dex in the perilymph: Dex is linear in the range of 10e5000 ng/ml. The RE of different concentrations of quality control samples was between À1.11% and 9.39%. The intra-and inter-day RSD values ranged from 3.51% to 5.41% and 3.19%e5.35%, respectively. All of the above data met the validation requirements of the biological sample analysis method.
Part 2
According to part 1, we determined the optimal time for each regimen when the Dex concentration in the cochlea was maximal. One hour, 4 h and 6 h were selected for immunofluorescence in the IP, IT and PA groups, respectively. A total of 16 guinea pigs were used in this part. After the animals were sacrificed, each cochlea was quickly removed from the skull and the middle ear. With the use of a microscope, the ossicles were removed, and small perforations were created in the otic capsule. All samples were postfixed in 4% paraformaldehyde for 24 h and then decalcified in 10% ethylenediaminetetraacetic acid (EDTA) for 7 days at 4 C. Subsequently, the samples were transitioned through a gradient of sucrose (30%), half optimal cutting temperature (OCT) compound in sucrose and 100% OCT compound for 24 h in each solution. The samples were then embedded in OCT compound on dry ice, sectioned at 8 mm and placed on glass slides for immunofluorescence.
Dex primary antibodies (Abcam 35000, Cambridge MA, USA) were diluted 1:250 in 20% normal goat serum (NGS) with 0.05% Triton X-100, applied to the sectioned tissues and incubated overnight at 4 C. Secondary antibodies (Abcam 150077, Cambridge MA, USA) were diluted 1:500 in 20% NGS with 0.05% Triton X-100 and incubated at room temperature for 2 h. The sections were then rinsed and co-labelled with 4',6-diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA, USA) before being mounted with VECTA-SHIELD (Vector Laboratories, Burlingame, CA, USA).
All tissue sections were reviewed, and those demonstrating appropriate cellular anatomy orientation and minimal fragmentation were selected for comparison. A LEICA TCS SP8 confocal scanning system (Leica, Germany) equipped with a Spectra Physics multi-line argon laser was used for high-resolution imaging. Confocal and laser settings were kept consistent to minimize variability among the groups. Using high-definition monitors, three independent reviewers subjectively assessed the relative intensity of labelling for Dex in the selected samples with the aid of Leica LAS X software (Leica, Germany).
Statistical analysis
SPSS software (version 21.0, IBM, USA) was used for the statistical analyses. The mean values were used to represent quantitative data, such as the Dex concentration and immunofluorescence intensity. The Shapiro-Wilk test was used to examine whether the measured values were normally distributed. The quantitative data were compared using the Kruskal-Wallis test. All reported p values are two-sided, and values less than 0.05 were considered to indicate statistical significance.
Results
LC-MS
The Dex concentrations in the perilymph and cochlear tissue were measured within 72 h using LC-MS. Figs. 1 and 2 show the time-related changes in the concentration of Dex in the cochlear tissue and perilymph, respectively, after administration by different methods. In the IP group, the highest concentrations of Dex were 238.17 ± 29.43 ng/ml in the cochlear tissue at 1 h and 100.87 ± 48.05 ng/ml in the perilymph at 2 h. In the IT group, the Dex concentration reached its highest levels in the cochlear tissue (28305 ± 5200.91 ng/ml) at 4 h and in the perilymph (25343.38 ± 2641.17 ng/ml) at 1 h. In the PA group, the cochlear tissue exhibited the highest concentration of Dex (1242.45 ± 173.08 ng/ml) at 6 h; however, the perilymph showed the highest concentration of Dex (532.56 ± 145.66 ng/ml) at 4 h. Comparisons of the maximal Dex concentrations in the perilymph and cochlear tissue after injection by three administration methods within 72 h is shown in Figs. 1 and 2 , respectively. The IT group revealed higher Dex concentrations in the perilymph and cochlear tissue than the PA and IP groups. Notably, the tissue measurements did not show a peak at the indicated time, but they were only measured at the specific time.
Immunofluorescence
Figs. 3 and 4 show representative images of the scala media (the organ of Corti and stria vascularis) and spiral ganglion in the four groups (the control, IP, IT and PA groups) at each optimal time after injection. Compared to the control group, fluorescence intensity was evident in the cochlear subsites in all three experimental groups, except for the tectorial membrane, where the cochleas of the control group also presented fluorescence intensity. Semiquantitative assessment of the mean grey immunofluorescence was conducted for the stria vascularis, organ of Corti, and spiral ganglion (Fig. 5) .
In the IP group, the stria vascularis exhibited the highest fluorescence intensity in all subsites in both the basal and apical portions. The intensity in the basal portions did not differ significantly from that in the apical portions. Compared to the cochleas in the IT group, the stria vascularis demonstrated greater immunofluorescence intensity.
In the IT group, the basal portions showed higher intensity than the apical portions. In the basal portions, the organ of Corti presented higher fluorescence intensity than the stria vascularis and spiral ganglion. However, the spiral ganglion showed the highest fluorescence intensity in the apical portions. The organ of Corti and basal portions showed greater immunofluorescence intensity in the IT group than those in the IP group.
In the PA group, the greatest fluorescence was present in the organ of Corti among all cochlear subsites. The intensity in basal portions did not differ significantly from that in apical portions. The organ of Corti (apical) showed greater fluorescence intensity in the PA group than in the IP group. However, the PA group showed greater fluorescence intensity in the scala media in the apical portions and stria vascularis compared to the IT group.
Discussion
In this study, using immunofluorescence and LC-MS, we simultaneously explored both the cochlear distribution and the Our results demonstrate that IT administration resulted in a significantly higher concentration of Dex in both the perilymph and cochlear tissue than IP administration at the studied times. In the IT group, the Dex concentration peaked in the perilymph at 1 h after injection. The IP group showed a very low Dex level in the perilymph and cochlear tissue. These findings indicate that Dex can successfully and easily penetrate the RWM and diffuse into the perilymph, and that only a few drugs can pass through the bloodlabyrinth barrier into the inner ear fluids by IP injection. These findings are consistent with those of many previous studies reporting significantly higher perilymph Dex concentrations after IT versus intravenous administration (Chandrasekhar et al., 2000; Yang et al., 2008) . The 3-layer RWM participates in secretion from and absorption by the perilymph. The outer epithelial layer contains some microvilli and abundant mitochondria, suggesting that it may be able to absorb substances and carry metabolic products. Either the substances are taken up into the blood vessels and/or lymphatic vessels and transported into the perilymph or they cross the inner epithelial layer to diffuse into the perilymph. The inner epithelial layer has areas of discontinuous basement membrane that may provide space through which substances can traverse the membrane. Various substances, including antibiotics, bactericides, metabolic products of arachidonic acid, toxins, steroids and tracers, have been reported to permeate the RWM to reach the perilymph (Yang et al., 2008) . The cochlear and perilymphatic concentrations of Dex in the IT group at the studied times were extremely higher than those in the IP group, suggesting that greater perilymph concentrations after IT administration may translate to higher cochlear tissue concentrations and that tissue penetration is proportionally related to the perilymph concentration.
Steroids affect SSNHL in many ways, such as by inhibiting immune responses, altering the microvascular circulation, exerting mineralocorticoid effects and reducing the endolymphatic pressure (Mort and Bronstein, 2006; Schreiber et al., 2010) . High local concentrations of Dex in the cochlear tissue are necessary and important for these effects. While studies have explored the pharmacokinetics of Dex in the cochlear perilymph (Bird et al., 2011; Piu et al., 2011; Salt et al., 2011 Salt et al., , 2012 Wang et al., 2009 Wang et al., , 2011 , some studies have reported that drugs in the perilymph can pass into the CSF via the cochlear aqueduct (Dean et al., 2012; Lee et al., 2012; Zhang et al., 2012) . In this study, we measured the time-dependent Dex concentration in cochlear tissue without perilymph to determine the optimal timing for IT, IP, and PA administration. Although the optimum concentration of steroid in the inner ear after administration is unknown, a relatively high concentration is favourable because there is currently no evidence of high-level steroid injury to the inner ear according to the literature (Alles et al., 2006; Yang et al., 2008) . Understanding the time course of steroid uptake and elimination from the cochlea is critical for the treatment of inner ear diseases. The results of this study demonstrate that IT administration results in a higher drug level and a longer drug duration in the cochlear tissue than PA and IP administration, suggesting that optimal timing may be more advantageous for treating inner ear diseases by IT rather than PA and IP administration. Simultaneously, the highest Dex concentration in the cochlear tissue in the IP, IT and PA groups appeared at 1, 4 and 6 h, respectively. The different peak concentrations and times to peak concentration suggest different delivery mechanisms of the three administration methods.
In this study, the times to the peak Dex concentrations in perilymph and cochlear tissue were always different from those in the local or systemic group. With IT application, the Dex concentration in cochlear tissue increased until 4 h as perilymph levels decreased; however, with IP application, perilymph levels increased until 2 h while cochlear tissue levels decreased. This phenomenon can be explained by the different pathways associated with IP and IT administration. IT Dex can diffuse into the subsites of cochlear tissue through the perilymph. Perilymph acts as an intermediary that allows Dex to diffuse throughout the cochlear tissue (Salt and Hirose, 2018) . Therefore, after IT administration, Dex can accumulate more quickly in perilymph than in cochlear tissue. With IP administration, Dex can reach the cochlear tissue via blood flow (Lee et al., 2018) . Creber et al. indicated that an abundant cochlear vascular network can potentially transfer systemic Dex to the cochlear tissue across the blood-labyrinth barrier (bypassing the perilymph as an intermediary) (Creber et al., 2018) . As a result, the time to reach the peak Dex concentration in cochlear tissue may be shorter than that of perilymph with IP administration.
Notably, we collected perilymph through the RMW of the cochlea in this study. This procedure of perilymph sampling may result in contamination with cerebrospinal fluid (CSF), and the concentration of Dex in perilymph samples may be underestimated (Salt et al., 2003) . However, the relative differences between the groups still remain valid because the same methodology was applied throughout the study (Wang et al., 2009) .
Because different inner ear diseases primarily damage different cochlear sites, it is necessary to choose the most appropriate route for steroid administration to treat inner ear diseases by understanding the distribution of steroids in the cochlea and how it differs depending on the administration route. To better understand the pharmacodynamics and distribution of Dex, the time at which each regime resulted in the maximal Dex concentrations in the cochlea was selected for immunofluorescence. In this study, the peak cochlear concentration of Dex appeared at 4 h in the IT group, 1 h in the IP group and 6 h in the PA group according to the pharmacokinetics of Dex in the cochlea. Regardless of the administration method used, the Dex level increased in the spiral ganglion, the organ of Corti and the lateral wall, which is in line with the distribution of the glucocorticoid receptor and consistent with previous studies (Grewal et al., 2013; Lee et al., 2018) . However, differences in Dex uptake by administration method were evident. Cochleas in the IP group showed higher fluorescence intensity in the organ of Corti compared with cochleas in the control group, indicating that systemic Dex can pass through the blood-labyrinth barrier and arrive at the organ of Corti. Compared to cochleas in the IT group, cochleas in the IP group showed greater fluorescence intensity in the stria vascularis. Our results contradict those of Creber's study, which indicated that IT administration allowed greater Dex penetration in the stria vascularis than systemic administration (Creber et al., 2018) . Dex could be delivered to cochlear tissues via different routes after injection via different methods. Dex administered systemically is transferred to cochlear subsites via blood flow (Lee et al., 2018) , but after IT administration, Dex can arrive at cochlear subsites through intracochlear diffusion (El et al., 2017; Salt and Hirose, 2018) . Our results indicated that the circulation can allow more Dex to arrive at the stria vascularis than intracochlear diffusion. However, in the IT group, the fluorescence intensity in the organ of Corti was highest in the cochlear tissue. This result is consistent with those of Harquani's study, which showed the highest Dex labelling in the organ of Corti but only slight Dex staining in the stria vascularis after IT administration (Hargunani et al., 2006) . In this study, the fluorescence intensity of the organ of Corti was greater in the IT group than that in the IP group. This result suggests that diffusion is more effective for delivering Dex to the organ of Corti than blood flow. This phenomenon could be explained by the relatively easy access between perilymph and the organ of Corti. Salt et al. (Salt and Hirose, 2018) pointed out that "In early anatomical studies, the basilar membrane, on which the organ of Corti rests, was first recognized as a prominent anatomic boundary and became defined as the boundary between scala tympani and scala media. The basilar membrane comprises layers of collagen fibers (Liu et al., 2015) , with a cellular, tympanic covering layer lacking tight junctions, thereby allowing it to be permeable to small molecules. The basilar membrane does not provide a barrier to the movement of fluid or small molecules". Intratympanic Dex administration could result in higher drug concentrations in the perilymph than systemic Dex administration, according to the LC-MS results. Higher drug concentrations in the perilymph could result in greater fluorescence intensity in the organ of Corti. Our study indicates that compared with traditional administration methods, IT administration results in higher Dex concentrations in the organ of Corti, while systemic administration results in higher Dex concentrations in the stria vascularis. Different inner ear diseases have different pathogenic mechanisms and cause injury to different cochlear sites (Creber et al., 2018) . The organ of Corti is the primary site of injury in noise-induced hearing loss and aminoglycoside-induced ototoxicity (Hirose et al., 2005; Sato et al., 2010) . However, the stria vascularis could be primarily damaged in autoimmune hearing loss and MD (Kariya et al., 2009; Lin et al., 1997; Ohlemiller et al., 2008; Tagaya et al., 2011) . Thus, these findings provide clinicians with an experimental basis for the efficacy of IT administration in treating noise-and aminoglycosideinduced hearing loss, as well as IP administration in treating autoimmune hearing loss and MD.
The Dex distribution in the apical and basal turns was also analysed in this study. Base-to-apex drug concentration gradients appeared in the IT group, consistent with many previous studies (Creber et al., 2018; Lee et al., 2018; Salt and Hirose, 2018) . Salt reported a substantial concentration gradient along the cochlea, with the 8-kHz regions exposed to a 500 Â higher drug concentration than the 500-Hz regions (Salt and Hirose, 2018) . Creber treated guinea pigs with Dex by IT injection and concluded that the basal immunofluorescence was greater than the apical immunofluorescence at all subsites after 60 min (Creber et al., 2018) . The cochlear distribution of a drug is primarily influenced by its diffusion and volume in fluids (Salt and Hirose, 2018) . First, Dex is readily permeable through membranous barriers (Salt and Hirose, 2018) . Second, the basal turn has a greater cross-sectional area than the apical turn, which can result in slower kinetics in the basal turn than in the apical turn. Third, the high permeability and fast kinetics in the apical turn result in transient drug exposure (Salt and Hirose, 2018) . The above factors all play important roles in the base-to-apex drug concentrations present in the IT group. The fluorescence intensity in the basal turn did not differ significantly from that in the apical turn after systemic dexamethasone administration. Lee reported no base-to-apex drug concentration gradient after IP administration of FITC-DEX, which is consistent with our results; he attributes this phenomenon to a complex vascular network extending across the length of the cochlea that eventually results in a uniform basal-to-apical distribution (Lee et al., 2018) . However, Grewal et al. reported that a decreasing basal-apical gradient of steroid uptake appears in hair cells after systemic injection (Grewal et al., 2013) .
Although many studies have indicated that IT administration results in higher perilymph concentrations and may be more effective for treating SSNHL, it is only effective for a certain percentage of patients with SSNHL (Ahn et al., 2008a,b; El et al., 2017; Stachler et al., 2012) , suggesting that IT administration may be appropriate for a certain type of SSNHL. The basal-apical drug gradient is evident, and more drug accumulates in basal portions after IT administration. In addition, the much longer scala tympani in humans (28.5 mm) than in guinea pigs (17.1 mm) could result in a more evident basal-apical drug gradient in the human cochlea (Creber et al., 2018; Salt et al., 2016) . However, uniform drug concentrations appear in the apical and basal portions after systemic administration, suggesting that while IT administration results in higher basal concentrations, systemic administration is more effective at delivering drugs to apical portions. Zou et al. confirmed by MRI that there is a more apical distribution of gadolinium after intravenous injection than after RWM delivery (Zou et al., 2009 ). These findings provide clinicians with a new approach for treating SSNHL based on the use of different administration methods for different types of SSNHL. IT administration is appropriate for treating high-frequency hearing loss corresponding to the cochlear base, but systemic administration is suitable for treating lowfrequency hearing loss corresponding to the cochlear apex. Similar results have also been found in terms of hearing protection with experimental cochlear implantation. Chang et al. demonstrated that high-frequency hearing can be protected in guinea pigs when Dex is applied to the RWM 30 min prior to cochlear implantation (Chang et al., 2009) . Connolly et al. demonstrated that systemic steroids can effectively protect hearing at lower frequencies in experimental cochlear implantation (Connolly et al., 2011) .
In our study, using LC-MS and immunofluorescence, we determined the maximal cochlear Dex concentrations at the studied times and the fluorescence intensity of cochlear subsites when each regimen produced the maximal Dex concentration in the cochlea. Interestingly, the ratio of maximal cochlear Dex concentrations between the IT and IP groups is approximately 118.9, which is significantly higher than the ratio of fluorescence intensities of cochlear subsites between the IT and IP groups, indicating that histologic tissue measurements of Dex may not accurately reflect the cochlear Dex concentration. Cochlear Dex includes free Dex and Dex bound to tissues. As immunofluorescence is complicated and requires many washing steps, histologic tissue measurements of Dex only reflect the portion bound to tissues that is not washed away during processing. Therefore, our results also indicate that despite the high Dex concentrations observed with IT administration, this administration resulted in a larger proportion of free Dex in the cochlea than IP administration. These results are consistent with a recent study demonstrating that the ratio of Dex in perilymph is significantly higher than the fluorescence intensity ratios of cochlear subsites between IP (2 mg/ml) and IT (5 ml, 200 mg/ml) groups (Creber et al., 2018) . Despite the high cochlear Dex concentration, cochlear-bound Dex seemed to be saturated due to limited glucocorticoid receptors (GR). There is clearly need to determine the optimal injection amount/concentration of Dex with different administration methods when cochlear-bound Dex is saturated.
PA steroids, which are characterized by reasonable therapeutic effects, minimal invasiveness and simplicity, have become widely used for treating inner ear diseases in China. The Chinese Society of Otorhinolaryngology Head and Neck Surgery released its latest version of guidelines for treating sudden deafness in 2015, which recommended the use of PA corticosteroids for patients who do not recover with systemic corticosteroids. In this study, fluorescence was primarily present in the organ of Corti and did not differ significantly between the apical and basal portions. These results indicate that PA administration is appropriate for inner ear diseases targeting the organ of Corti regardless of apical or basal position. Different drug concentrations in the perilymph/cochlea and the cochlear distribution may indicate that Dex arrives in the cochlea by a different route after PA versus IP and IT administration. The following mechanism could explain this phenomenon. With PA administration, some of the Dex can enter the systemic circulation via the posterior auricular vein and ultimately arrive in the cochlea via blood flow, which may explain why greater fluorescence intensity was observed in the stria vascularis in the PA group compare to the IT group. However, another portion of the drug could pass through natural fractures, which exist between the PA position and middle ear, to reach the middle ear, ultimately arriving in the perilymph via the RWM. Cros et al. used micro-CT scan to discover that numerous micro-channels were present between the surface of the mastoid bone and the middle ear in humans (Cros et al., 2013 (Cros et al., , 2016 . This mechanism may explain why the PA group showed higher drug concentrations in the perilymph and cochlea compared with the IP group. Compared to IT administration, PA administration resulted in a lower cochlear Dex concentration, but this administration method has many advantages, such as minimal invasiveness, simplicity and absence of a basal-apical drug gradient. However, Dex pathways associated with PA injection in the guinea pig may differ considerably from those in humans, where the lengths of such pathways are greater. A method that is effective in a very small structure, such as an otocyst, may not necessarily be effective in a larger structure. Studies on the route by which substances (especially steroids) move from the postaural area to the middle ear are limited (Li et al., 2013) . Further studies on the mechanism of PA drug administration should be conducted in the future.
In conclusion, this study not only measured the pharmacokinetics and distribution of Dex in the cochlea after traditional (IT and IP) injection methods but also after a newer injection method, PA, which is popular in China. Cochleas treated with IT dexamethasone presented higher maximal Dex concentrations and longer Dex durations than those treated with PA and IP Dex. Different administration methods have different Dex distribution characteristics, which are attributed to features of the cochlear vascular system and intracochlear diffusion. Intratympanic and postaural administration could result in higher Dex concentrations in the organ of Corti than systemic administration, but systemic administration could result in higher Dex concentrations in the stria vascularis than the other administration methods. A decreasing basal-apical gradient of Dex uptake was present in the cochlea after IT administration but not after IP or PA administration. These results may provide clinicians with an experimental basis for the use of different Dex injection routes to achieve optimal effects in treating different inner ear diseases with different target organs.
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